Description_x000D_ Application_x000D_ DL-Homocysteine has been used to induce hyperhomocysteinemia in Sprague–Dawley rats. It has also been used to study the effects of hyperhomocysteinemia on atherosclerosis in apolipoprotein E-deficient mice._x000D_ Packaging_x000D_ 1, 5, 25 g in poly bottle_x000D_ 10 mg in autosample vial_x000D_ Biochem/physiol Actions_x000D_ Homocysteine is a sulfhydryl-containing amino acid, synthesized from methionine. It is a non-essential, non-proteinogenic amino acid. It is an important determinant of the methylation cycle and is present in the plasma in four forms. An abnormally high level of homocysteine leads to hyperhomocysteinemia and also promotes atherosclerosis._x000D_ Increased plasma homocysteine is a risk factor for coronary heart disease and carcinogenesis; may be a marker for tumor cell growth._x000D_ Other Notes_x000D_ Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. H4628.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.